

Press Release

For Immediate Release

Health Innovation: AusMed Global Signs Strategic Partnership with Merck

Extending Market Coverage of The World's leading Non-invasive Breath Ketone Management Technology from Hong Kong to Global and Transforming Diabetes and Obesity Care

(Hong Kong, 29 July 2024) – AusMed Global, a partner company of the Hong Kong Science and Technology Parks Corporation (HKSTP) signed a strategic partnership with Merck, the leading science and technology company. This partnership enhances broader access of the world's leading non-invasive diabetes management solutions to international markets and accelerating advancements in diabetes and obesity cares.

AusMed's KetoMetrics, the pioneering non-invasive breath ketone management system utilizes photonic sensing technology to measure breath acetone, offering a painless alternative to traditional blood testing. Similar to blood prick tests, the 'one test, one kit' approach minimizes carryover contamination. Additionally, the use of single-use breath samplers enhances the hygiene of each test, making KetoMetrics a proper choice for measurement in the point-of-care setting. This cutting-edge solution will bring advancements in diabetes and lifestyle management.

Ms. Christine Yip, CEO & Founder of AusMed, said, “KetoMetrics is the company's revolutionary solution for diabetes and lifestyle management, offering a non-invasive and efficient method to enhance patient care and improve health outcomes. This partnership with Merck, supported by HKSTP, marks a significant milestone in our journey, enhancing broader access to the non-invasive diabetes management solutions and accelerating advancements in diabetes and obesity cares. We are excited about the potential of this collaboration to set new standards in healthcare innovation and patient care, and to continue pushing the boundaries of what's possible in diabetes and obesity management.

Mr. Tony Cheng, Managing Director of Merck HK, said “As a science and technology company, Merck believes to advance the patients' health through partnership, we are keen to promote the best start-up company that augment the landscape of diabetic care. We look forward to providing beyond the pills solution that will benefit patients in need and make a positive impact on the wider community.” Tony also highlighted the strategic partnership between Merck and AusMed is strengthened by their longstanding relationship with HKSTP. It aims to accelerate the commercialization of innovative solutions for diabetes management, potentially transforming the care landscape for patients.

Dr Grace Lau, Head of Institute for Translational Research of HKSTP said, “We are thrilled to see the partnership between Merck and AusMed. This collaboration will bring AusMed's innovative healthcare solution to an even wider customer base and make a more impactful contribution to the community. HKSTP is committed to fostering healthcare innovation. This introduction set the stage for a day of groundbreaking revelations and collaborative discussions.”

HKSTP is committed to propelling the park companies to expand their sales networks and enhance their visibility and connectivity with industry leaders. With AusMed's professional knowledge, rich industry experience in the pharmaceutical field, and world-class technology, this strategic partnership is an excellent example of the vibrant innovation and technology (I&T) ecosystem attract high-potential startups, accelerate their growth, and bring widespread benefits to patients. This collaboration further cements Hong Kong's position as an international hub of biomedical innovation.

Photo download [here](#).



Photo 1: Ms Christine Yip, CEO & Founder, AusMed Global (front row, left) and Mr Tony Cheng, Managing Director of Merck HK & Macau (front row, right) signed a strategic partnership with Merck, the leading science and technology company, extending market coverage of the world's leading non-invasive breath ketone management technology from Hong Kong to global and transforming diabetes and obesity care. The signing ceremony is witnessed by Mr Rob Donnelly, Senior Trade and Investment Commissioner/ Deputy Consul General (Commercial), Austrade, Australian Consulate (last row, left) and Dr Grace Lau, Head of Institute for Translational Research, HKSTP (last row, right).



Photo 2: This partnership leverages both AusMed's innovative KetoMetrics technology and Merck's extensive healthcare expertise, enhancing broader access to non-invasive diabetes management solutions and accelerating advancements in diabetes and obesity cares.

###

About AusMed

AusMed Global Limited (AusMed) was founded in late 2017 and headquartered in Hong Kong Science and Technology Park. It is a fast-growing life science company specializing in developing novel non-invasive medical devices and solutions for home and point-of-care uses in response to the global challenges in diabetes, overweight, and obesity.

Its breakthrough non-invasive photonic sensing technology for monitoring diabetes, which was pioneered by Sydney University's initial technology, and later on developed over 6 years by AusMed R&D team to achieve breakthrough at HKSTP, has been patented in numerous countries including US, Europe, Australia and China. The novel KetoMetrics high-performance breath ketone analyser system is a game changer in ketone measurement with accuracy and selectivity comparable to the gold standard GC. It aims at providing a quick and accurate non-invasive measurement method for diabetic ketoacidosis (DKA) and ketosis (fat metabolism) management. The KetoMetrics AI management system and app for diet management promotes a healthy lifestyle and wellness.

AusMed obtained ISO13485 and ISO9001 certificates, and is a FDA registered medical device establishment. AusMed is a winner of the Judges' Recognition Award of the HKABA NSW Chapter Business Awards 2021, and the Silver Medal of the 2022 Geneva International Exhibition of Inventions for its "High-Performance Fat Loss Management Solution". People's Choice Award in the InsurTech Insights Asia 2023. Named MedTech Innovator Asia-Pacific 2024.

For more information, please visit: <https://www.ausmedglobal.com.hk/about>



About Merck

Merck, a leading science, and technology company, operates across healthcare, life science and electronics. Around 60,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2021, Merck generated sales of €19.7 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck's technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics.

For more information, please visit: <https://www.merckgroup.com/en>

About Hong Kong Science and Technology Parks Corporation

Hong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 12 unicorns, more than 14,000 research professionals and over 1,800 technology companies from 29 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc.

Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined.

Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more.

Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues contribute in establishing I&T as a pillar of growth for Hong Kong.

More information about HKSTP is available at www.hkstp.org.



Media Contact:
**Hong Kong Science and Technology Parks
Corporation**
Angela Lau
Tel: +852 2629 6633
Email: angela.lau@hkstp.org